Related Experiment Video
Updated: Nov 11, 2025
12:16
High Throughput Quantitative Expression Screening and Purification Applied to Recombinant Disulfide-rich Venom Proteins Produced in E. coli
Published on: July 30, 2014
24.5K
Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins
Bach-Ngan Nguyen1,2, Florian Tieves1, Thomas Rohr1,3
1NUMAFERM GmbH, Merowingerplatz 1a, 40225, Düsseldorf, Germany.
AMB Express
|March 25, 2021
Summary
A novel Numaswitch technology enables efficient recombinant production of diverse peptides, overcoming challenges like degradation and aggregation. This platform yields high-quality active pharmaceutical ingredients (APIs) cost-effectively, demonstrated by Teriparatide production.
Area of Science:
- Biotechnology
- Pharmaceutical Sciences
- Protein Engineering
Background:
- Recombinant peptide production for active pharmaceutical ingredients (APIs) faces challenges including proteolytic sensitivity, aggregation, and cytotoxicity.
- Existing production platforms lack reliability for diverse peptide characteristics.
Purpose of the Study:
- To introduce and validate a novel technology, Numaswitch, for overcoming limitations in recombinant peptide production.
- To demonstrate the versatility and cost-efficiency of Numaswitch for producing various peptides and small proteins.
Main Methods:
- Development of the Numaswitch technology platform.
- Application of Numaswitch for the production of diverse peptides and small proteins, including Teriparatide, Linaclotide, human β-amyloid, and Serum amyloid A3.
- Evaluation of production yield and API quality standards.
Main Results:
- Numaswitch successfully addressed limitations such as proteolytic sensitivity and aggregation in peptide production.
- The technology was effective for producing a range of peptides and small proteins with varying characteristics.
- Demonstrated high yield of Teriparatide (> 2 g/L) meeting API standards.
Conclusions:
- Numaswitch represents a reliable and versatile platform for recombinant peptide and small protein production.
- The technology offers a potential solution for cost-efficient commercial manufacturing of peptide-based APIs.
- Numaswitch facilitates the production of complex peptides, expanding therapeutic possibilities.
Keywords:
Active pharmaceutical ingredientsHigh-titer peptide expression platformLiraglutideNumaswitchPTH(1-34)PTH(1-84)Recombinant peptidesSemaglutideSwitchtagTeriparatide
